Ovidrel and Progesterone HRT: What You Need to Know About This Drug Combination

What Is the Interaction Between Ovidrel and Progesterone HRT?

The short answer: there is no clinically significant pharmacokinetic interaction between Ovidrel and progesterone. These two drugs do not compete for the same metabolic enzymes, and neither drug meaningfully alters the blood levels of the other.

What does exist between them is a pharmacodynamic relationship, meaning they work together biologically in a deliberate, sequential way. Ovidrel mimics the LH surge that triggers follicle rupture and ovulation. Progesterone, given afterward, sustains the endometrial lining and corpus luteum function so that a fertilized egg can implant and early pregnancy can be maintained. Understanding this sequence, and the timing errors that can disrupt it, matters far more than worrying about a drug-drug interaction in the classical pharmacological sense.

How Ovidrel Works in the Body

Choriogonadotropin alfa is a recombinant form of human chorionic gonadotropin (hCG). After a subcutaneous 250 mcg injection, it binds to LH/hCG receptors on granulosa and luteal cells, triggering the final maturation of oocytes and corpus luteum formation. Peak serum hCG is reached at approximately 39 hours post-injection, and the half-life is roughly 29 hours, meaning detectable hCG from the trigger shot can persist for up to 10 days after injection.

This is clinically relevant for you if you're doing an at-home pregnancy test after an IUI or timed intercourse cycle: a positive test within 10 days of the Ovidrel shot may reflect residual trigger hCG, not an early pregnancy signal.

How Progesterone HRT Works in Fertility Protocols

In natural cycles, the corpus luteum (the structure left behind after ovulation) produces progesterone for 10 to 14 days. In stimulated cycles, ovarian hyperstimulation and egg retrieval can impair corpus luteum function, making exogenous progesterone supplementation mandatory rather than optional. ASRM practice guidelines confirm that luteal-phase support with progesterone significantly improves live birth rates in IVF cycles, and the benefit is considered sufficiently established that omitting it is not standard of care.

Pharmacokinetics and Metabolism: Why There Is No CYP Interaction

This section gets slightly technical, but knowing the mechanism helps you understand why your reproductive endocrinologist isn't worried about a drug-drug interaction here.

CYP Enzyme Involvement

Ovidrel (choriogonadotropin alfa) is a glycoprotein hormone. It is not metabolized by cytochrome P450 enzymes. It is cleared primarily through renal excretion and receptor-mediated degradation. The FDA prescribing information for Ovidrel does not list any CYP-based interactions, and no significant interactions with other reproductive hormones have been identified in the pharmacokinetic studies submitted for approval.

Micronized progesterone (Prometrium) is metabolized primarily in the liver via CYP3A4, CYP2C19, and aldo-keto reductase enzymes, producing metabolites including allopregnanolone, which has mild sedative properties. However, because Ovidrel does not touch the CYP system, there is no mechanism by which it would alter progesterone metabolism or blood levels.

P-glycoprotein and Transporter Involvement

Neither choriogonadotropin alfa nor micronized progesterone is a clinically significant substrate, inhibitor, or inducer of P-glycoprotein or the major hepatic uptake transporters (OATP1B1, OATP1B3). The FDA drug interaction guidance framework confirms no transporter-based interaction signals for either agent.

Vaginal and IM Progesterone: Even Less Systemic Overlap

Vaginal progesterone (Crinone 8% gel or Endometrin 100 mg inserts) achieves high local uterine concentrations through what is called the "first uterine pass effect" while producing lower systemic serum levels than oral or IM routes. Vaginal progesterone reaches endometrial tissue concentrations two to three times higher than serum levels would predict, which is why your clinic may choose the vaginal route specifically for endometrial support. This route has minimal hepatic involvement, making the theoretical CYP concern essentially zero.

The Real Clinical Consideration: Timing and Sequence

The interaction that actually matters here is not a drug interaction. It is a timing interaction. Getting the sequence wrong between Ovidrel and progesterone supplementation can impair implantation or trigger premature luteinization.

Why Progesterone Timing Relative to Ovidrel Matters

Progesterone initiated too early, before the Ovidrel-triggered ovulation window has closed, can cause premature endometrial maturation. This shortens the implantation window and reduces the probability of successful implantation. For frozen embryo transfer (FET) cycles, where natural ovulation is suppressed and the endometrium is prepared with exogenous estrogen and progesterone, the timing of progesterone start determines the precise window of uterine receptivity. Most FET protocols begin progesterone 5 to 6 days before a day-5 blastocyst transfer, calibrated to match embryo developmental age to endometrial readiness.

For IUI or timed intercourse cycles using Ovidrel as a trigger, progesterone supplementation is typically begun 1 to 3 days post-trigger, once ovulation has been confirmed or assumed to have occurred (approximately 36 to 40 hours post-injection). Your reproductive endocrinologist will give you a specific day to start, and that instruction should be followed precisely.

Luteal Phase Adequacy in Stimulated vs. Natural Cycles

In a natural cycle, the corpus luteum self-regulates progesterone output through endogenous LH. In a gonadotropin-stimulated cycle (for IUI or IVF), multiple follicles develop, and after egg retrieval or ovulation, multiple corpora lutea form simultaneously. This sounds like a progesterone surplus, but the opposite problem often occurs: supraphysiologic estrogen levels generated during stimulation suppress pituitary LH, leaving the corpus lutea undersupported. A Cochrane review of luteal phase support in ART confirmed that progesterone supplementation reduces miscarriage risk and improves ongoing pregnancy rates versus placebo.

Sex-Specific Physiology: How Your Hormonal Status Changes the Picture

Reproductive Years (Age 18-40)

In your reproductive years using Ovidrel as part of an IUI or IVF protocol, the progesterone you are given is active reproductive support, not HRT in the traditional sense. The doses are generally higher than those used in menopausal hormone therapy: Prometrium 200 mg vaginally twice daily or progesterone in oil 50 mg IM daily are common luteal support regimens, compared with 100 mg oral Prometrium nightly for a postmenopausal woman on HRT.

If you have PCOS, your baseline progesterone dynamics differ from women with regular ovulation. Anovulatory PCOS cycles have no corpus luteum and no endogenous post-ovulatory progesterone rise. If Ovidrel successfully triggers ovulation in a PCOS cycle, luteal support with exogenous progesterone is particularly important because PCOS-associated LH dysregulation may impair corpus luteum function even after a successful trigger.

Perimenopause and Diminished Ovarian Reserve

Some women in perimenopause undergo fertility treatment with Ovidrel as an ovulation trigger and need simultaneous progesterone support during the luteal phase. In this life stage, ovarian reserve is declining, corpus luteum function may be compromised, and the hormonal fluctuations of perimenopause add complexity. Diminished ovarian reserve is associated with reduced luteal phase progesterone even after successful ovulation, making exogenous progesterone support more, not less, important.

If you are perimenopausal and also using low-dose progesterone HRT (for example, as part of a combined estrogen-progesterone HRT regimen for hot flashes or cycle regulation), and you are simultaneously undertaking fertility treatment with Ovidrel, your reproductive endocrinologist needs to know about all hormones you are taking. The HRT progesterone dose and formulation may need to be adjusted or temporarily replaced by the fertility protocol's luteal support regimen to avoid redundancy or timing confusion.

Postmenopause

Postmenopausal women do not use Ovidrel. It is indicated for ovulation induction, and postmenopausal ovaries do not have follicles to stimulate or ovulate. Progesterone HRT in postmenopause serves a completely different purpose: endometrial protection in women using systemic estrogen therapy. This article does not apply to that postmenopausal context beyond noting the distinction clearly.

Pregnancy and Lactation Safety

This section is required for all drug articles on WomanRx and cannot be skipped.

Ovidrel in Pregnancy

Ovidrel is FDA Pregnancy Category X when used for any purpose other than ovulation induction in the context of assisted reproductive technology. This means it carries a risk designation that warns against use in already-pregnant women outside of its labeled fertility indication.

However, early in pregnancy, hCG levels from a naturally implanting embryo mirror the pharmacological hCG from Ovidrel. The drug is not expected to be harmful to an established early pregnancy at the single-dose trigger level, and clinicians do not interrupt ART cycles if a positive pregnancy test follows an Ovidrel trigger. Once pregnancy is confirmed, Ovidrel is not re-administered; luteal support continues with progesterone alone.

No teratogenicity has been established for hCG at doses used clinically. Contraception is not a requirement around Ovidrel use because the drug is used specifically to achieve pregnancy. If you are not pursuing pregnancy and are using Ovidrel for any off-label reason (which would be unusual), discuss timing carefully with your prescribing physician.

Progesterone in Pregnancy

Micronized progesterone is FDA Pregnancy Category B. It has been used for decades in ART luteal support and is continued through gestational weeks 8 to 10 in most IVF protocols, until placental progesterone production (the "luteo-placental shift") is sufficient to maintain the pregnancy independently. Vaginal progesterone has also been studied for the prevention of preterm birth in women with a short cervix, as evaluated in the PROGRESS and OPPTIMUM trials, though findings there are specifically about cervical length screening, not the fertility context.

Progesterone does not cross into breast milk in clinically significant quantities at standard doses, making it generally compatible with lactation. Women breastfeeding while using progesterone-only contraception (the mini-pill or progestogen-only HRT) are not typically counseled to discontinue breastfeeding.

Contraception Requirements

No contraception requirement applies to Ovidrel because it is used expressly to support conception. If a cycle fails and you do not become pregnant, your fertility team will advise on the subsequent cycle plan.

Who This Combination Is Right for, and Who It Is Not

Right For

You are likely being given both drugs appropriately if you are:

• Undergoing IUI with controlled ovarian stimulation and Ovidrel as a trigger, with progesterone luteal support added 1 to 3 days post-trigger
• In an IVF fresh embryo transfer cycle where progesterone begins the day after egg retrieval
• In a frozen embryo transfer cycle where progesterone starts 5 to 6 days before the planned blastocyst transfer
• Perimenopausal and pursuing fertility treatment with a monitored, protocol-driven approach under a reproductive endocrinologist

Not Right For (or Requires Clarification)

This combination needs a direct conversation with your care team if you are:

• Using over-the-counter progesterone cream alongside Ovidrel without medical supervision. Transdermal over-the-counter "progesterone" products typically deliver insufficient progesterone to maintain adequate luteal support, and their absorption is highly variable
• Taking progesterone HRT for menopausal symptoms and not undergoing active fertility treatment. The HRT progesterone dose (100 mg oral nightly) is not equivalent to fertility luteal support dosing
• Also taking any strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampicin) alongside oral progesterone, as these may alter oral progesterone metabolism, even though Ovidrel itself is uninvolved

The WomanRx Ovidrel-Progesterone Decision Framework: A useful way to think about this combination across life stages is to ask three sequential questions. First: what is the progesterone for (luteal support for implantation, or systemic HRT for menopausal symptoms)? Second: is the dose matched to the clinical goal? Third: is the timing relative to the Ovidrel trigger correct for the specific protocol being used (IUI, fresh IVF, or FET)? Getting all three right matters far more than worrying about a pharmacokinetic interaction that does not exist.

Sedation Overlap: The One Side Effect Worth Monitoring

The research passage for this interaction flags "sedation overlap" as a risk profile element. Here is what that means in practice.

Micronized progesterone (Prometrium) generates a metabolite called allopregnanolone, a positive allosteric modulator of GABA-A receptors. This is the same mechanism behind brexanolone (Zulresso) for postpartum depression, though at much lower concentrations with oral progesterone. At standard doses of 200 mg oral micronized progesterone taken at bedtime, a meaningful proportion of women report drowsiness, which is why clinicians routinely recommend taking it at night.

Ovidrel itself does not cause sedation. It is a single subcutaneous injection given once per cycle, typically in the evening, with ovulation expected approximately 36 hours later. The temporal overlap (both given in the evening, Ovidrel on trigger night and progesterone starting a few days later) means there is no simultaneous sedation signal.

If you are prescribed oral progesterone at higher doses (some protocols use 400 mg nightly orally), drowsiness can be more pronounced. Vaginal or IM progesterone bypasses the CNS-active metabolite pathway largely because vaginal administration avoids first-pass hepatic conversion to allopregnanolone, which is one clinical reason some women prefer or are switched to vaginal formulations if oral Prometrium causes excessive sedation.

Monitoring and Dose Adjustment Considerations

No dose adjustment of either Ovidrel or progesterone is required due to their co-administration. What your care team will monitor includes:

• Serum progesterone on days 5-7 post-trigger (or post-transfer): A serum progesterone level below 10 ng/mL in the mid-luteal phase of an IUI cycle, or below the protocol-specific threshold in an IVF cycle, may prompt a dose increase in supplemental progesterone
• Ultrasound confirmation of ovulation 36-48 hours post-Ovidrel: If follicle rupture is not confirmed, the progesterone start may be delayed or the cycle cancelled
• Beta-hCG at 9-14 days post-trigger: To distinguish residual Ovidrel hCG from early pregnancy hCG, many clinicians time the first beta test at 14 days post-trigger (14 days post-IUI), when Ovidrel signal should have cleared from a 250 mcg dose in most women. A single 250 mcg Ovidrel dose typically clears to below 5 mIU/mL by day 10-14 post-injection in most women
• Thyroid function: Not directly related to this drug pair, but women with PCOS or those in perimenopause pursuing fertility treatment have elevated rates of thyroid dysfunction, and subclinical hypothyroidism reduces IVF success rates. A TSH check is reasonable before any stimulated cycle

Evidence Gaps in Women-Specific Research

Women have been historically underrepresented in pharmacokinetic drug-drug interaction studies, and the Ovidrel-progesterone pairing is no exception to that broader pattern. The statement that no pharmacokinetic interaction exists between choriogonadotropin alfa and progesterone is based on the absence of shared metabolic pathways identified in regulatory submissions, not from a dedicated women's study comparing co-administration against either drug alone in a randomized trial. This absence-of-evidence point should be taken as reassuring but not as definitive proof of zero interaction at the pharmacodynamic level in every possible clinical scenario.

ASRM guidelines on luteal phase support draw on dozens of randomized trials of progesterone formulations in ART, but most of these trials were not designed to evaluate interactions with the specific hCG trigger used. The clinical confidence in this combination comes from decades of standard practice in reproductive medicine, not from head-to-head interaction studies. Where you are using a newer formulation of progesterone (such as a vaginal ring or subcutaneous injection), data on direct comparison to the standard protocols is thinner, and you should ask your reproductive endocrinologist what the evidence base is for the specific product they are prescribing.